Semaglutide vs AOD-9604: Weight Loss Evidence Gap

Semaglutide (Wegovy, Ozempic) is an FDA-approved GLP-1 receptor agonist with robust clinical evidence for weight loss. AOD-9604 is an experimental HGH fragment with minimal human data. This comparison highlights the evidence gap: semaglutide is proven; AOD-9604 is speculative.

Mechanism: GLP-1 receptor agonist; reduces appetite, increases satiety, slows gastric emptying, improves glucose control.

Human evidence: Multiple large randomized controlled trials (STEP 1-4) in over 4,500 patients. Average weight loss 15-22% of body weight over 68 weeks. FDA-approved for chronic weight management (Wegovy).

Effect size: Highest among any weight loss medication; approximately 15-22 kg over 1 year in clinical trials.

Side effects: Common: nausea, vomiting, diarrhea, constipation (dose-dependent, often improve over time). Rare: pancreatitis, thyroid concerns (preclinical signals).

Safety profile: Well-characterized; active pharmacovigilance post-approval. Long-term data available (2+ years).

Cost: $300-1,500/month depending on formulation and source.

Accessibility: FDA-approved prescription; widely available (though expensive).

Mechanism: HGH fragment; stimulates lipolysis, increases metabolic rate.

Human evidence: One small pilot study (~80 patients) showing modest fat loss (~5 kg over 12 weeks). No large randomized controlled trials published.

Effect size: Small; estimated 5 kg or less over 12 weeks (weak evidence).

Side effects: Minimal reported; generally well-tolerated (very limited data).

Safety profile: Poorly characterized; long-term safety unknown.

Cost: $100-250/month.

Accessibility: Research chemical; not FDA-approved.

Semaglutide advantages: - 15-22 kg loss (proven) vs. AOD-9604's ~5 kg (speculative) - FDA-approved with regulatory oversight - Large, rigorous trials (4,500+ patients) vs. small pilot - Well-characterized safety vs. unknown long-term effects - Prescription access vs. black market

AOD-9604 should not be considered as alternative: - Evidence gap is massive (22 kg proven vs. 5 kg experimental) - No large human trials published - Safety profile unknown long-term

Bottom line: If weight loss is your goal, use semaglutide. AOD-9604 is not a viable alternative based on current evidence.